Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Sepia Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 distinct examiners and 3 art units, indicating a fully distributed examination profile.
GULLEDGE, BRIAN M is the busiest examiner, with 1 pending matter. Counsel should tailor each response to its examiner and art unit while coordinating positions only where the records support doing so.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.9% | +26.2% |
| MCLEOD, AFRICA MHAIRIE | 1 | 52.8% | +67.7% |
| HASAN, KHALEDA B | 1 | 59.3% | +49.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 31d overdue |
| 17929828 | COMPOSITIONS AND METHODS FOR MODULATING FORKHEAD BOX P3 (FOXP3) GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 31d overdue |
| 18556563 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | GULLEDGE, BRIAN M | — |
| 17929828 | COMPOSITIONS AND METHODS FOR MODULATING FORKHEAD BOX P3 (FOXP3) GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1635 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18556563 | TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES | GULLEDGE, BRIAN M | 1637 | §103 | Non-Final OA | — | Pending | Oct 20, 2023 |
| 17929828 | COMPOSITIONS AND METHODS FOR MODULATING FORKHEAD BOX P3 (FOXP3) GENE EXPRESSION | MCLEOD, AFRICA MHAIRIE | 1635 | §101§102§103 | Final Rejection | — | Pending | Sep 06, 2022 |
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | HASAN, KHALEDA B | 1636 | §102§103§112 | Final Rejection | 31d overdue | Pending | Mar 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSepia Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Brian M Gulledge has the most, with 1 of Sepia Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
